Lv4
520 积分 2021-07-07 加入
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
28天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches
2个月前
已完结
Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X
4个月前
已完结
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
4个月前
已完结
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
4个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
6个月前
已完结
Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts
6个月前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
7个月前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
7个月前
已关闭
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
7个月前
已完结
皖公网安备34019202002308
